Scarica l'app Stockscreener
2.91
2.35%
-0.07
Dopo l'orario di chiusura:
2.88
-0.03
-1.03%
Precedente Chiudi:
$2.98
Aprire:
$3
Volume 24 ore:
40,658
Relative Volume:
0.78
Capitalizzazione di mercato:
$26.15M
Reddito:
$442.00K
Utile/perdita netta:
$-30.46M
Rapporto P/E:
-0.6525
EPS:
-4.46
Flusso di cassa netto:
$-27.47M
1 W Prestazione:
-3.96%
1M Prestazione:
+8.18%
6M Prestazione:
-49.57%
1 anno Prestazione:
-66.54%
Intervallo 1D:
$2.85
$3.08
Intervallo di 1 settimana:
$2.85
$3.1299
Portata 52W:
$2.57
$9.20
Clene Inc Stock (CLNN) Company Profile
Nome
Clene Inc
Settore
Industria
Telefono
801-676-9695
Indirizzo
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Confronta CLNN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
2.91 | 26.15M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
28.59 | 34.72B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
55.05 | 30.53B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.61 | 28.52B | 12.63B | 1.38B | 863.00M | 3.96 |
|
MKC
Mccormick Co Inc
|
75.30 | 20.04B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
29.21 | 16.23B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-02 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-28 | Iniziato | Oppenheimer | Outperform |
Clene Inc Borsa (CLNN) Ultime notizie
Geode Capital Management LLC Grows Stake in Clene Inc. (NASDAQ:CLNN) - Defense World
Clene Inc. Enters Agreement for $25M Equity Distribution By Investing.com - Investing.com Nigeria
Clene Inc. Enters Agreement for $25M Equity Distribution - Investing.com Australia
Clene Inc.Enters Equity Distribution Agreement With CanaccordSEC Filing - marketscreener.com
Analysts Set Clene Inc. (NASDAQ:CLNN) Target Price at $55.25 - Defense World
Clene (NASDAQ:CLNN) Research Coverage Started at Jones Trading - Defense World
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResear - GuruFocus
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResearch | CLNN Stock News - GuruFocus
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - The Manila Times
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference - The Globe and Mail
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com India
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
Clene (NASDAQ:CLNN) Earns Buy Rating from D. Boral Capital - The AM Reporter
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - Barchart.com
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo
Clene Inc Azioni (CLNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Clene Inc Azioni (CLNN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Mar 18 '25 |
Sale |
4.45 |
1,333 |
5,932 |
712,252 |
| MATLIN DAVID J | Director |
Sep 30 '24 |
Buy |
4.75 |
92,307 |
438,458 |
444,491 |
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
0.62%
1.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):